Amplify Seymour Cannabis ETF

Curaleaf Holdings, Inc. released FY2026 Q1 earnings on May 5 After-Market EST, actual revenue USD 324.23 M (forecast USD 317.05 M), actual EPS USD 0.0895

Curaleaf reports Q1 gross profit of $157.3 million

Curaleaf Holdings Schedules Annual and Special Meeting

Curaleaf Holdings Fully Acquires Four 20 Pharma

Curaleaf Completes Acquisition of Four 20 Pharma to Strengthen European Market Position

Curaleaf Holdings, Inc. to Release FY2026 Q1 Earnings on May 5 After-Market EST, Forecast Revenue USD 317.05 M

Curaleaf Holdings, Inc. Launches $83 Million Stock Repurchase Program

Curaleaf Inc stock price gaps down, revenue exceeds expectations

Curaleaf Holdings, Inc. released FY2025 Annual Earnings on February 27 After-Market (EST), Actual Revenue: USD 1.268 B (Forecast: USD 1.274 B), Actual EPS: USD -0.3587

Curaleaf Holdings, Inc. released FY2025 Q4 earnings on February 27 After-Market (EST), actual revenue USD 323.36 M (forecast USD 329.25 M), actual EPS USD -0.0904

Curaleaf Holdings, Inc. to Release FY2025 Q4 Earnings on February 26 After-Market EST, Forecast Revenue USD 328.27 M

Curaleaf Reports Strong Q4 Earnings and Plans to Exit Missouri Market

Curaleaf Holdings, Inc. released FY2025 Q3 earnings on November 6 After-Market (EST), actual revenue USD 320.24 M (forecast USD 316.87 M), actual EPS USD -0.0838

Curaleaf Holdings, Inc. released FY2025 9 Months Earnings on November 6 After-Market EST, with actual revenue of USD 944.77 M and EPS of USD -0.2695

Curaleaf Holdings, Inc. to Release FY2025 Q3 Earnings on November 5 After-Market EST, Forecast Revenue USD 317.11 M

Curaleaf Holdings, Inc. released FY2025 Q2 earnings on August 6 After-Market EST, actual revenue USD 314.52 M (forecast USD 313.92 M), actual EPS USD -0.0839

Curaleaf Holdings, Inc. released FY2025 Semi-Annual Earnings on August 6 After-Market EST, with actual revenue of USD 621.14 M and EPS of USD -0.1874

Curaleaf Holdings, Inc. to Release FY2025 Q2 Earnings on August 6 After-Market EST, Forecast Revenue USD 314.71 M

Curaleaf Holdings, Inc. released FY2025 Q1 earnings on May 8 After-Market EST, actual revenue USD 310.01 M (forecast USD 311.26 M), actual EPS USD -0.0998

Curaleaf Holdings, Inc. to release FY2025 Q1 earnings on May 8 After-Market EST, forecast revenue USD 314.07 M

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

MSOS

CNBS

The AdvisorShares Pure US Cannabis ETF (MSOS) has seen a significant increase of 31% in one month and 69% over the past year, largely due to its holdings in US multi-state operators benefiting from potential Section 280E tax relief if cannabis rescheduling occurs. The Amplify Seymour Cannabis ETF (CNBS) provides diversified exposure to the US cannabis market.

AdvisorShares Pure US Cannabis ETF

Cannabis rescheduling could unlock the biggest MSO rally since 2021

WEED

YOLO

President Trump announced plans to reschedule marijuana from Schedule I to Schedule III under the Controlled Substances Act, providing a boost to cannabis stocks that have faced significant losses over the past five years. This announcement follows an executive order aimed at increasing funding and research for psilocybin and other substances.

Roundhill Cannabis ETF

Amplify Alternative Harvest ETF

AdvisorShares Pure Cannabis ETF

Trump's rescheduling of marijuana is a spark for top marijuana ETFs

The cannabis sector is experiencing volatility driven by three key catalysts. Recent federal reforms have led to the rescheduling of medical cannabis, potentially injecting $2 billion into company balance sheets. However, a lawsuit from prohibitionists could create stock weakness. Additionally, the possibility of retroactive tax relief under IRS Rule 280E and a hearing on recreational cannabis rescheduling in mid-2026 could further impact the market. Investors should monitor these developments for potential entry and exit points.

CabotWealthNetwork

Curaleaf Holdings, Inc.

Green Thumb Industries Inc.

3 Catalysts Driving Cannabis Sector Volatility in 2026

MSOX

512690

TOKE

SNDL (NASDAQ:SNDL) reported a 4.4% year-over-year decline in net revenue to $196 million and a gross profit decrease of 6.8% to $53 million in its Q1 2026 earnings call. The decline was attributed to challenges in the liquor and cannabis markets, alongside working capital management issues. However, the company anticipates profitability improvements from initiatives aimed at generating over $20 million in incremental operating income this year. SNDL is optimistic about future growth, particularly in international sales, and is actively utilizing its share repurchase program due to perceived undervaluation of shares.

benzinga_article

AdvisorShares MSOS 2x Daily ETF

Penghua CSI Alcoholic Drink ETF

Cambria Cannabis ETF

SNDL

Full Transcript: SNDL Q1 2026 Earnings Call

Avicanna Inc. has welcomed the U.S. Department of Justice's decision to reschedule certain cannabinoid-based products from Schedule I to Schedule III, aligning with its pharmaceutical strategy. This change is expected to enhance R&D, clinical development, and patient access. The company is advancing its clinical trials, including studies on THC for anxiety and pain management. Avicanna continues to expand its medical cannabis initiatives and is well-positioned to leverage its intellectual property for future U.S. market entry, focusing on pharmaceutical development and strategic partnerships.

StockTitan

iShares US Pharma

Avicanna Welcomes Initial U.S. Rescheduling of Medical Cannabis & Provides Scientific Update | AVCNF Stock News

Illinois' cannabis industry may benefit from a federal decision to reclassify marijuana, potentially lowering costs for businesses and facilitating medical research. This reclassification could ease tax burdens and expand research opportunities, as federal officials have recently taken significant steps toward changing marijuana's drug category.

What marijuana reclassification means for Illinois

MJUS

Cannabis providers hailed the decision, calling it the most consequential federal marijuana policy shift in decades.

Amplify US Alternative Harvest ETF

Cannabis stocks lose buzz despite this landmark decision

CRON

CURLF

GTBIF

TCNNF

CRLBF

Trump administration to reclassify marijuana as Schedule III, easing research barriers but not legalizing the drug or changing current federal penalties.

Cronos

Trulieve Cannabis Corp.

Cresco Labs Inc.

Aurora Cannabis

Trump administration reclassifies cannabis in major shift that could expand scientific research

TLRY

Cannabis stocks surged on Wednesday following reports of the Trump administration's plan to reclassify marijuana, potentially aligning it with less-restricted substances. Tilray Brands (TLRY) rose 14%, Canopy Growth (CGC) increased 21%, and Curaleaf (CURLF) climbed 26%. Other cannabis stocks and ETFs also saw gains. Seeking Alpha's quant ratings show most cannabis names hold ratings, with Tilray receiving a 'Strong Sell' at 1.36, while others like MariMed (MRMD) and Cronos Group (CRON) hold ratings around 3.21 and 3.13, respectively.

Tilray Brands

Canopy Growth

Quant snapshot on cannabis names as Trump plans reclassification

Shares of cannabis-related stocks are trading higher following a report suggesting that the Trump administration is expected to move to reclassify marijuana as soon as Wednesday.

Amplify Seymour Cannabis ETF(CNBS.US)

Cannabis rescheduling could unlock the biggest MSO rally since 2021

Trump's rescheduling of marijuana is a spark for top marijuana ETFs

3 Catalysts Driving Cannabis Sector Volatility in 2026

Full Transcript: SNDL Q1 2026 Earnings Call

Avicanna Welcomes Initial U.S. Rescheduling of Medical Cannabis & Provides Scientific Update | AVCNF Stock News